Clinical response to glatiramer acetate correlates with modulation of IFN-γ and IL-4 expression in multiple sclerosis

R. M. Valenzuela, K. Costello, M. Chen, A. Said, K. P. Johnson, Suhayl Dhib-Jalbut

Research output: Contribution to journalArticle

Abstract

Objective: To determine whether glatiramer acetate (GA)-induced lymphoproliferation and IFN-γ and IL-4 modulation correlate with the clinical response in multiple sclerosis (MS). Background: GA therapy involves the induction of anti-inflammatory cytokine shifts. However, it is not known whether this response correlates with the clinical outcome. Methods: Thirty-six relapsing-remitting (RR) MS patients were treated with GA for at least two years, and classified clinically as GA-responders (GA-R = 22) or hypo/non-responders (GA-HR/NR = 14). Proliferation of peripheral blood mononuclear cells (PBMC) to GA and Tetanus toxoid (TT), as well as IL-4 and IFN-γ ELISPOT, were performed. Findings: There was no difference in PBMC proliferation to GA or TT between GA-R and GA-HR/NR before and during treatment (P>0.05). The mean number of IFN-γ ELISPOTS in unstimulated, TT and anti-CD3/ CD28-stimulated PBMC was lower among GA-R (unstimulated: GA-R = 10.1 ± 6.21 (n=22) versus GA-HR/NR=17.8±12.7 (n=14), P=0.04; TT-GA-R=12.2±4.06 (n=12) versus GA-HR/NR=26.8±21.0 (n=8), P=0.028; anti-CD-3/CD28 GA-R=217.3+140.4 (n=22) versus GA-HR/ NR=368.5±170.1 (n=14), P=0.006). In contrast, the number of IL-4ELISPOTS remained unchanged in the GA-R group, but was progressively reduced in the GA-HR/NR group during GA therapy (GA-HR/NR IL-4: pre-Rx: 59±34 versus 22±11 at 12 months (n =6), P=0.0429). The IL-4/IFN-γ ratio in anti-CD3/CD28-stimulated PBMC was significantly higher among GA-R compared to GA-HR/NR (P = 0.0474). Interpretation: Lymphoproliferation to GA did not differentiate GA-R from CA-HR/NR. However, reduced IFN-γ expression and stable IL-4 expression in anti-CD3/CD28-stimulated PBMC, and an increased IL-4/ IFN-γ ratio was associated with favorable clinical response. More data are needed to validate the prospective use of IL-4/IFN-γ expression in PBMC as a biomarker of clinical response to GA for individual patients.

Original languageEnglish (US)
Pages (from-to)754-762
Number of pages9
JournalMultiple Sclerosis
Volume13
Issue number6
DOIs
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

Interleukin-4
Multiple Sclerosis
Blood Cells
Tetanus Toxoid
Glatiramer Acetate
Enzyme-Linked Immunospot Assay
Relapsing-Remitting Multiple Sclerosis

Keywords

  • Glatiramer acetate
  • Interferon-gamma
  • Interleukin-4
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Clinical response to glatiramer acetate correlates with modulation of IFN-γ and IL-4 expression in multiple sclerosis. / Valenzuela, R. M.; Costello, K.; Chen, M.; Said, A.; Johnson, K. P.; Dhib-Jalbut, Suhayl.

In: Multiple Sclerosis, Vol. 13, No. 6, 07.2007, p. 754-762.

Research output: Contribution to journalArticle

Valenzuela, R. M. ; Costello, K. ; Chen, M. ; Said, A. ; Johnson, K. P. ; Dhib-Jalbut, Suhayl. / Clinical response to glatiramer acetate correlates with modulation of IFN-γ and IL-4 expression in multiple sclerosis. In: Multiple Sclerosis. 2007 ; Vol. 13, No. 6. pp. 754-762.
@article{fcd5e5dcd15f4eabbca3e5c67d93d2ef,
title = "Clinical response to glatiramer acetate correlates with modulation of IFN-γ and IL-4 expression in multiple sclerosis",
abstract = "Objective: To determine whether glatiramer acetate (GA)-induced lymphoproliferation and IFN-γ and IL-4 modulation correlate with the clinical response in multiple sclerosis (MS). Background: GA therapy involves the induction of anti-inflammatory cytokine shifts. However, it is not known whether this response correlates with the clinical outcome. Methods: Thirty-six relapsing-remitting (RR) MS patients were treated with GA for at least two years, and classified clinically as GA-responders (GA-R = 22) or hypo/non-responders (GA-HR/NR = 14). Proliferation of peripheral blood mononuclear cells (PBMC) to GA and Tetanus toxoid (TT), as well as IL-4 and IFN-γ ELISPOT, were performed. Findings: There was no difference in PBMC proliferation to GA or TT between GA-R and GA-HR/NR before and during treatment (P>0.05). The mean number of IFN-γ ELISPOTS in unstimulated, TT and anti-CD3/ CD28-stimulated PBMC was lower among GA-R (unstimulated: GA-R = 10.1 ± 6.21 (n=22) versus GA-HR/NR=17.8±12.7 (n=14), P=0.04; TT-GA-R=12.2±4.06 (n=12) versus GA-HR/NR=26.8±21.0 (n=8), P=0.028; anti-CD-3/CD28 GA-R=217.3+140.4 (n=22) versus GA-HR/ NR=368.5±170.1 (n=14), P=0.006). In contrast, the number of IL-4ELISPOTS remained unchanged in the GA-R group, but was progressively reduced in the GA-HR/NR group during GA therapy (GA-HR/NR IL-4: pre-Rx: 59±34 versus 22±11 at 12 months (n =6), P=0.0429). The IL-4/IFN-γ ratio in anti-CD3/CD28-stimulated PBMC was significantly higher among GA-R compared to GA-HR/NR (P = 0.0474). Interpretation: Lymphoproliferation to GA did not differentiate GA-R from CA-HR/NR. However, reduced IFN-γ expression and stable IL-4 expression in anti-CD3/CD28-stimulated PBMC, and an increased IL-4/ IFN-γ ratio was associated with favorable clinical response. More data are needed to validate the prospective use of IL-4/IFN-γ expression in PBMC as a biomarker of clinical response to GA for individual patients.",
keywords = "Glatiramer acetate, Interferon-gamma, Interleukin-4, Multiple sclerosis",
author = "Valenzuela, {R. M.} and K. Costello and M. Chen and A. Said and Johnson, {K. P.} and Suhayl Dhib-Jalbut",
year = "2007",
month = "7",
doi = "10.1177/1352458506074510",
language = "English (US)",
volume = "13",
pages = "754--762",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Clinical response to glatiramer acetate correlates with modulation of IFN-γ and IL-4 expression in multiple sclerosis

AU - Valenzuela, R. M.

AU - Costello, K.

AU - Chen, M.

AU - Said, A.

AU - Johnson, K. P.

AU - Dhib-Jalbut, Suhayl

PY - 2007/7

Y1 - 2007/7

N2 - Objective: To determine whether glatiramer acetate (GA)-induced lymphoproliferation and IFN-γ and IL-4 modulation correlate with the clinical response in multiple sclerosis (MS). Background: GA therapy involves the induction of anti-inflammatory cytokine shifts. However, it is not known whether this response correlates with the clinical outcome. Methods: Thirty-six relapsing-remitting (RR) MS patients were treated with GA for at least two years, and classified clinically as GA-responders (GA-R = 22) or hypo/non-responders (GA-HR/NR = 14). Proliferation of peripheral blood mononuclear cells (PBMC) to GA and Tetanus toxoid (TT), as well as IL-4 and IFN-γ ELISPOT, were performed. Findings: There was no difference in PBMC proliferation to GA or TT between GA-R and GA-HR/NR before and during treatment (P>0.05). The mean number of IFN-γ ELISPOTS in unstimulated, TT and anti-CD3/ CD28-stimulated PBMC was lower among GA-R (unstimulated: GA-R = 10.1 ± 6.21 (n=22) versus GA-HR/NR=17.8±12.7 (n=14), P=0.04; TT-GA-R=12.2±4.06 (n=12) versus GA-HR/NR=26.8±21.0 (n=8), P=0.028; anti-CD-3/CD28 GA-R=217.3+140.4 (n=22) versus GA-HR/ NR=368.5±170.1 (n=14), P=0.006). In contrast, the number of IL-4ELISPOTS remained unchanged in the GA-R group, but was progressively reduced in the GA-HR/NR group during GA therapy (GA-HR/NR IL-4: pre-Rx: 59±34 versus 22±11 at 12 months (n =6), P=0.0429). The IL-4/IFN-γ ratio in anti-CD3/CD28-stimulated PBMC was significantly higher among GA-R compared to GA-HR/NR (P = 0.0474). Interpretation: Lymphoproliferation to GA did not differentiate GA-R from CA-HR/NR. However, reduced IFN-γ expression and stable IL-4 expression in anti-CD3/CD28-stimulated PBMC, and an increased IL-4/ IFN-γ ratio was associated with favorable clinical response. More data are needed to validate the prospective use of IL-4/IFN-γ expression in PBMC as a biomarker of clinical response to GA for individual patients.

AB - Objective: To determine whether glatiramer acetate (GA)-induced lymphoproliferation and IFN-γ and IL-4 modulation correlate with the clinical response in multiple sclerosis (MS). Background: GA therapy involves the induction of anti-inflammatory cytokine shifts. However, it is not known whether this response correlates with the clinical outcome. Methods: Thirty-six relapsing-remitting (RR) MS patients were treated with GA for at least two years, and classified clinically as GA-responders (GA-R = 22) or hypo/non-responders (GA-HR/NR = 14). Proliferation of peripheral blood mononuclear cells (PBMC) to GA and Tetanus toxoid (TT), as well as IL-4 and IFN-γ ELISPOT, were performed. Findings: There was no difference in PBMC proliferation to GA or TT between GA-R and GA-HR/NR before and during treatment (P>0.05). The mean number of IFN-γ ELISPOTS in unstimulated, TT and anti-CD3/ CD28-stimulated PBMC was lower among GA-R (unstimulated: GA-R = 10.1 ± 6.21 (n=22) versus GA-HR/NR=17.8±12.7 (n=14), P=0.04; TT-GA-R=12.2±4.06 (n=12) versus GA-HR/NR=26.8±21.0 (n=8), P=0.028; anti-CD-3/CD28 GA-R=217.3+140.4 (n=22) versus GA-HR/ NR=368.5±170.1 (n=14), P=0.006). In contrast, the number of IL-4ELISPOTS remained unchanged in the GA-R group, but was progressively reduced in the GA-HR/NR group during GA therapy (GA-HR/NR IL-4: pre-Rx: 59±34 versus 22±11 at 12 months (n =6), P=0.0429). The IL-4/IFN-γ ratio in anti-CD3/CD28-stimulated PBMC was significantly higher among GA-R compared to GA-HR/NR (P = 0.0474). Interpretation: Lymphoproliferation to GA did not differentiate GA-R from CA-HR/NR. However, reduced IFN-γ expression and stable IL-4 expression in anti-CD3/CD28-stimulated PBMC, and an increased IL-4/ IFN-γ ratio was associated with favorable clinical response. More data are needed to validate the prospective use of IL-4/IFN-γ expression in PBMC as a biomarker of clinical response to GA for individual patients.

KW - Glatiramer acetate

KW - Interferon-gamma

KW - Interleukin-4

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=34447536807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447536807&partnerID=8YFLogxK

U2 - 10.1177/1352458506074510

DO - 10.1177/1352458506074510

M3 - Article

C2 - 17613604

AN - SCOPUS:34447536807

VL - 13

SP - 754

EP - 762

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 6

ER -